A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease

Margaret L. MacMillan, Daniel Couriel, Daniel J. Weisdorf, Gisela Schwab, Nancy Havrilla, Thomas R. Fleming, Saling Huang, Lorin Roskos, Shimon Slavin, Richard K. Shadduck, John DiPersio, Mary Territo, Steve Pavletic, Charles Linker, Helen E. Heslop, H. Joachim Deeg, Bruce R. Blazar

Research output: Contribution to journalArticle

65 Scopus citations

Fingerprint Dive into the research topics of 'A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds